Upfront Briefing
Ipsen yanked Tazverik globally over safety concerns — the rare kind of update that turns revenue expectations into a hard zero.
Elsewhere, Vertex posted a late-stage IgA nephropathy win, while Servier kept biotech M&A alive with its $2.5B move for Day One; Dianthus, meanwhile, moved quickly to capitalize on an open financing window.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,796.0 |
+0.8% |
(0.7%) |
| Nasdaq 100 |
24,967.3 |
+1.3% |
(1.1%) |
| Russell 2000 |
2,553.7 |
+1.1% |
+2.9% |
| Healthcare (XLV) |
154.3 |
+1.0% |
(0.3%) |
| Biotech (XBI) |
127.1 |
+2.5% |
+4.3% |
| Nasdaq Biotech (NBI) |
5,901.0 |
+1.9% |
+3.4% |
| Clinical Trials (BBC) |
42.6 |
+2.9% |
+10.5% |
|
- Biotech led Monday’s rebound: XBI (+2.5%) and BBC (+2.9%) both outpaced the S&P 500 (+0.8%) as investors rotated back into higher-beta healthcare.
- The sector move looked catalyst-backed rather than purely macro: Vertex’s late-stage IgA nephropathy win added a real pipeline positive, while trial-stage biotech caught a bid as sentiment around FDA oversight improved.
- BBC was the standout mover on the sheet, consistent with investors leaning back into clinical-risk names when both the tape and the regulatory tone turn more constructive.
- Market data: U.S. cash close Mon 09-Mar-2026.
The Big 3
|
1
|
Ipsen withdraws cancer drug Tazverik due to safety concerns
|
-
Ipsen has withdrawn its cancer drug Tazverik from the market globally due to emerging safety concerns.
-
Why it matters:
This is more than a product revenue hit. A global safety-led withdrawal wipes out remaining Tazverik cash flows, raises questions around lifecycle value from the Epizyme deal, and reminds investors that even marketed oncology assets can still carry late-emerging risk.
-
Source:
Endpoints
-
More:
PR
|
|
2
|
Vertex reports late-stage IgA nephropathy biomarker win
|
-
Vertex announced positive late-stage results for its IgA nephropathy drug, showing a successful reduction in a key kidney disease biomarker.
-
Why it matters:
For Vertex, this is exactly the kind of late-stage proof point investors want from the post-CF pipeline: a potentially differentiated kidney asset with filing visibility, meaningful commercial potential, and a chance to validate the broader immunology/nephrology expansion story.
-
Source:
STAT
-
More:
BioPharma Dive
|
|
3
|
Servier to acquire Day One Biopharmaceuticals for $2.5B
|
-
Servier agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash, valuing the company at about $2.5 billion and adding pediatric low-grade glioma drug Ojemda.
-
Why it matters:
This is the cleanest proof that strategic buyers are still willing to pay meaningful premiums for differentiated commercial-stage oncology assets. For investors, it reinforces that the M&A bid is alive for companies with approved products, focused launch stories and scarce pediatric/rare oncology exposure.
-
Source:
Reuters
|
Everything Else that broke
- Bristol Myers reports mezigdomide success in multiple myeloma. — BioPharma Dive
- Mineralys NDA accepted for lorundrostat; PDUFA date set. — PR
- Coherus Oncology reports FY/Q4 2025 results and update. — PR
- Design Therapeutics reports Q4/FY 2025 results and updates. — PR
- Voyager reports Q4/FY 2025 financial and operating results. — PR
- West Pharmaceutical Services CEO Eric Green says he plans to retire. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
- Servier to acquire Day One Biopharmaceuticals for $2.5B in cash, adding pediatric low-grade glioma drug Ojemda and deepening its rare oncology footprint. — Reuters
VC / Private Financings
- No notable VC / private biotech financings identified in the last 24 hours.
IPOs / Follow-Ons
- Dianthus proposes a $400M underwritten public offering following its early Phase 3 GO decision in CIDP. — PR
Academic Corner
- A daily multivitamin slows the ticking of epigenetic clocks. — Nature Medicine
- Microbiome modulation in cancer immunotherapy. — Nature Medicine
- Effects of daily multivitamin–multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial. — Nature Medicine
- Synthetic lethal strategy targets p53-deficient cancers. — Nature RDD
|
